IgA-Modified Gastrointestinal Contents for IBD Flora Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) focus on symptomatic relief but fail to address the underlying intestinal flora imbalance, leading to disease exacerbation due to antibiotic-resistant bacteria and varying patient responses.
Innovation Solution
A method involving gastrointestinal contents or excretions modified with IgA antibodies to restore the bacterial flora, administered to IBD patients, and a composition containing these modified contents to treat IBD, along with methods for obtaining and testing IgA antibodies that enhance bacterial diversity and reduce harmful bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If antibiotics are administered to eliminate pathogenic bacteria, then the number of enteritis-causing bacteria is reduced, but fermentative bacteria are eliminated together with pathogenic bacteria and antibiotic-resistant bacteria become dominant, leading to increased disease severity
Solution Approach 1:
The patent extracts and administers IgA antibodies specifically targeting pathogenic bacteria from the patient's own intestinal environment. This selective extraction allows elimination of only the harmful bacteria while preserving beneficial fermentative bacteria, avoiding the collateral damage caused by broad-spectrum antibiotics.
Solution Approach 2:
IgA antibodies serve as a mediator between the immune system and pathogenic bacteria. These antibodies specifically bind to and neutralize enteritis-causing bacteria through their adhesiveness and invasiveness targets, enabling selective elimination without affecting other bacterial populations.
2Object-affected harmful factors
If a single drug is used to suppress inflammation in IBD patients, then the active phase symptoms are controlled, but the varying intestinal florae of different patients cannot be addressed, making radical cure difficult
Solution Approach 1:
The patent applies local quality by customizing the IgA antibody treatment to each patient's specific intestinal flora composition. The antibodies are derived from individual patient samples, creating a personalized therapeutic profile that addresses the unique bacterial landscape of each patient rather than applying a uniform treatment approach.
Solution Approach 2:
The patent performs preliminary analysis of each patient's intestinal flora composition before administering treatment. By characterizing the specific bacterial profile in advance, the treatment can be tailored to target the particular pathogenic bacteria present in each patient, enabling proactive and personalized intervention.
3Adaptability or versatility
If bacterial preparation or fecal transplantation is administered to improve intestinal flora, then there is a certain therapeutic effect, but a novel therapeutic method is still needed
Solution Approach 1:
The patent creates a simplified copy of the healthy intestinal flora state by administering purified IgA antibodies that replicate the protective function of normal intestinal immunity. Rather than transplanting complex fecal material, the invention copies the essential protective mechanism through specific antibody administration, reducing complexity while maintaining efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively restores the bacterial flora, reducing IBD-related bacteria and improving symptoms by enhancing bacterial diversity and short-chain fatty acid content, providing a personalized treatment approach.
Implementation Method 1
gastrointestinal contents or excretions modified with IgA antibodies that restore the bacterial flora
Data Source
AI summary
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.